...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >GPX3 methylation is associated with hematologic improvement in low-risk myelodysplastic syndrome patients treated with Pai-Neng-Da
【24h】

GPX3 methylation is associated with hematologic improvement in low-risk myelodysplastic syndrome patients treated with Pai-Neng-Da

机译：<斜视> GPX3 甲基化与用Pai-neng-da治疗的低危髓细胞增强症患者的血液学改善有关

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective The aim of this prospective randomized controlled clinical trial was to explore the relationship between GPX3 methylation and Pai-Neng-Da (PND) in the treatment of patients with low-risk myelodysplastic syndrome (MDS). Methods There were 82 low-risk MDS patients who were randomly divided into the following two groups: androl, thalidomide, and PND capsule (ATP group, n?=?41); or androl and thalidomide (AT group, n?=?41). Hemoglobin and neutrophil and platelet counts and changes in GPX3 methylation level were assessed. Results The plasma hemoglobin level increased in both groups after treatment. However, the platelet count increased only in the ATP group. Patients in the ATP group had a better platelet response than the AT group, and GPX3 methylation markedly decreased after treatment with ATP but not after treatment with AT. Moreover, male patients had a significantly lower GPX3 methylation level than female patients, while platelet counts from male patients increased dramatically after the ATP regimens compared with female patients. GPX3 methylation changes were negatively correlated with platelet changes in ATP group. Conclusion PND can improve hematological parameters and decrease the GPX3 methylation level. Decreasing GPX3 methylation is associated with the hematologic response that includes platelet in GPX3 methylation. China Clinical Trial Bureau (ChiCTR; http://www.chictr.org.cn/ ) registration number : ChiCTR-IOR-15006635.
机译：目的对该前瞻性随机对照临床试验的目的是探讨GPX3甲基化和PAI-NENG-DA（PND）在治疗低风险骨髓增生术综合征（MDS）的患者之间的关系。方法有82例低风险的MDS患者，随机分为以下两组：Androl，沙利度胺和PND胶囊（ATP组，N？= 41）;或androl和沙利度胺（在组，n？= 41）。评估血红蛋白和中性粒细胞和血小板计数和GPX3甲基化水平的变化。结果治疗后两组血浆血红蛋白水平增加。然而，血小板计数仅在ATP组中增加。 ATP组的患者具有比AT组更好的血小板响应，并且在用ATP处理后，GPX3甲基化显着降低，但在用AT处理后没有显着降低。此外，男性患者比女性患者显着降低GPX3甲基化水平，而在ATP方案与女性患者相比，男性患者的血小板计数急剧增加。 GPX3甲基化变化与ATP组的血小板变化呈负相关。结论PND可改善血液学参数并降低GPX3甲基化水平。降低GPX3甲基化与包括GPX3甲基化中的血小板的血液学反应有关。中国临床试验局（CHICTR; http://www.chictr.org.cn/）注册号：CHICTR-IOR-15006635。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号